期刊文献+

Effect Observation of Clinical Treatment with Oxaliplatin and Tiggio for Biliary Tract Tumors on Advanced Stage

下载PDF
导出
摘要 Objective:To investigate the effect of oxaliplatin combined with tiggio in the treatment of advanced biliary tract tumors.Methods:The research period was from November 2019 to November 2020.80 patients with advanced biliary tumor disease were enrolled.They were divided into groups according to the order of admission,with 40 cases in each group.The control group received oxaliplatin combined with gemcitabine,and the experimental group received oxaliplatin combined with tiggio.Incidence of adverse reactions,time to disease progression,survival time and clinical efficacy were checked and assessed.Results:Compared with the incidence of adverse reaction of the experimental group,which was 5.00%(2/40),the incidence of adverse reaction of the control group was 25.00%(10/40).The chi-square value=6.2745,p-value=0.0122.The time to progression and survival time of patients in the experimental group were shorter than those of the control group,with significant differences between the groups(p<0.05);the clinical efficacy of the experimental group and the control group were 97.50%(39/40)and 77.50%(31/40)respectively,the comparative chi-square value=7.3143,p-value=0.0068.Conclusion:The combined treatment of oxaliplatin and Tiggio in the treatment of advanced biliary tract tumors has higher safety and reduces the incidence of adverse reactions.
出处 《Journal of Clinical and Nursing Research》 2021年第3期66-68,共3页 临床护理研究(英文)
  • 相关文献

参考文献4

二级参考文献29

  • 1Furuse J, Okusaka T, Boku N, et al. S-1 monotherapy as first-line treat- ment in patients with advanced biliary tract cancer:a multicenter phase II study [ J ]. Cancer Chemother Pharmaco1,2008,62 ( 5 ) : 849 - 855.
  • 2Sasaki T, Isayama H, Nakai Y, et al. Multieenter, phase II study of gemeitabine and S-1 combination chemotherapy in patients with ad- vanced biliary tract cancer [ J ]. Cancer Chemother Pharmacol, 201 O, 65 (6) :1101 - 1107.
  • 3Adelsberger H, Quasthoff S,Grosskreutz J, et al. The chemotherapeutic oxali- platin alters voltage-gated Na ( + ) channel kinetics on rat senso- ry neurons[ J]. Eur J Pharmacol,2000,406 (1):25 -32.
  • 4Hezel AF,Zhu AX. Systemic therapy for biliary tract cancers[ J]. On- cologist, 2008,13 ( 4 ) :415 - 423.
  • 5Valle J,Wasan H, Palmer HD,et al. Cisplatin plus gemcitabine versus gemci- tabine for biliary tract cancer [ J]. N Engl J Med, 2010,362 (14) :1273 - 1281.
  • 6Kim M J, Oh DY, Lee SH, et al. Gemcitabine-based versus fluoropyrimi- dine- based chemotherapy with or without platinum in unresectable bili- ary tract cancer:a retrospective study[ J]. BMC Cancer,2008,8:374.
  • 7Kang MJ,Lee JL,Kim TW,et al. Randomized phase II trial of S-I and cisplatin versus gemcitabine and cisplatin in patients with advanced bil- iarytract adenocar-cinoma [ J ]. Acta Onco1,2012, 51 (7) : 860 - 866.
  • 8Ueno H,Okusaka T,Ikeda M, et al. Phase II study of S-1 in patients with advanced biliary tract cancer [ J ]. Br J Cancer, 2004,91 ( 10 ) : 1769 - 1774.
  • 9Kim YJ,Im SA,Kim HG,et al. A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer[ J]. Ann Oncol, 2008,19(1) :99 -103.
  • 10Kim K,Jang G,Hong YS,et al. Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clin-ical activity [ J ]. British Journal of Cancer, 2011,104 ( 4 ) : 605 - 612.

共引文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部